Sector Update: Healthcare Stocks Rise Tuesday Afternoon

MT Newswires Live02:02

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) gaining 1.2%.

The iShares Biotechnology ETF (IBB) increased 0.5%.

In sector news, Nourish, a nutrition counseling startup focused on supporting patients using GLP-1 weight-loss drugs, raised $100 million in a Series C funding round led by Menlo Ventures, the company said Tuesday. The round included participation from Thrive Capital, Index Ventures, JPMorgan Chase's (JPM) growth equity arm, Maverick Ventures, Y Combinator and others, the company said.

In corporate news, Boston Scientific (BSX) shares gained 1.4% after the company said Tuesday that a trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.

Relay Therapeutics (RLAY) shares climbed 5.2% after it said early phase 2 data showed its experimental drug zovegalisib reduced lesion volume in patients with rare vascular anomalies linked to PIK3CA mutations.

Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the company said. Its shares rose 3.7%.

MetaVia (MTVA) shares were up 58% in Tuesday trading, a day after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment